{
    "ticker": "ATNF",
    "name": "Athenex, Inc.",
    "description": "Athenex, Inc. is a global biopharmaceutical company dedicated to the development and commercialization of innovative therapies for cancer treatment. Founded in 2003 and headquartered in Buffalo, New York, Athenex focuses on harnessing the power of its proprietary technologies to enhance the effectiveness of existing cancer therapies and to develop new treatment options. The company\u2019s lead product candidate, KUR-501, is an innovative T-cell therapy designed to target and attack cancer cells, offering hope for patients with significant unmet medical needs. Athenex is committed to advancing its robust pipeline, which includes both proprietary and partnered programs in various stages of clinical development. The company\u2019s mission is to improve the lives of cancer patients through science and innovation, and it actively collaborates with leading research institutions and other biopharmaceutical companies to accelerate the development of its products. Athenex\u2019s commitment to patient-centered care drives its research efforts, as it seeks to create therapies that not only extend life but also enhance the quality of life for patients battling cancer.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Buffalo, New York, USA",
    "founded": "2003",
    "website": "https://www.athenex.com",
    "ceo": "Dr. Johnson Lau",
    "social_media": {
        "twitter": "https://twitter.com/Athenex",
        "linkedin": "https://www.linkedin.com/company/athenex"
    },
    "investor_relations": "https://ir.athenex.com",
    "key_executives": [
        {
            "name": "Dr. Johnson Lau",
            "position": "CEO"
        },
        {
            "name": "Dr. Aijun Wang",
            "position": "President"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Therapies",
            "products": [
                "KUR-501",
                "KUR-902"
            ]
        },
        {
            "category": "Drug Development",
            "products": [
                "Oral Chemotherapy"
            ]
        }
    ],
    "seo": {
        "meta_title": "Athenex, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Athenex, Inc., a biopharmaceutical leader in developing innovative cancer therapies. Learn about their mission and products aimed at improving patient outcomes.",
        "keywords": [
            "Athenex",
            "Cancer Treatment",
            "Biopharmaceuticals",
            "KUR-501",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What is Athenex known for?",
            "answer": "Athenex is known for its innovative cancer therapies and drug development focused on improving outcomes for cancer patients."
        },
        {
            "question": "Who is the CEO of Athenex?",
            "answer": "Dr. Johnson Lau is the CEO of Athenex, Inc."
        },
        {
            "question": "Where is Athenex headquartered?",
            "answer": "Athenex is headquartered in Buffalo, New York, USA."
        },
        {
            "question": "What are Athenex's main products?",
            "answer": "Athenex's main products include KUR-501 and oral chemotherapy formulations."
        },
        {
            "question": "When was Athenex founded?",
            "answer": "Athenex was founded in 2003."
        }
    ],
    "competitors": [
        "NVS",
        "MRK",
        "PFE",
        "AMGN"
    ],
    "related_stocks": [
        "JNJ",
        "ABBV",
        "GILD",
        "BMY"
    ]
}